(BFM Bourse) – The pharmaceutical group presented positive results on Sunday in the treatment of chronic obstructive pulmonary disease at an international congress. Fitch, for its part, raised Sanofi’s credit rating. Sanofi is poised to succeed where competitors AstraZeneca and GSK have failed in chronic obstructive pulmonary disease (COPD), nicknamed “smoker’s bronchitis”. COPD is a…
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service providers. They are kept for the duration of the processing and/or for the duration of the specific processing to which you have consented and/or for…
(CercleFinance.com) – Sanofi gained almost 5% in Paris, taking advantage of its results on Dupixent and an analysis by Oddo which confirmed its outperformance rating, with an unchanged price target of 105 euros. The analysis office thus judges as “extremely positive for the group” the positive results of the trial evaluating Dupixent in chronic bronchitis…
sanofi (photo credit: Adobe Stock / ) (CercleFinance.com) – Sanofi announces that its Dupixent could become the first biological drug against chronic obstructive pulmonary disease (COPD), after a pivotal phase III study showing a significant reduction in exacerbations, compared to a placebo. In adults on maximum standard inhaled therapy (triple therapy) with uncontrolled COPD with…
(AOF) – Largest increase in the CAC 40, Sanofi gained 4.44% to 94.89 euros after announcing that Dupixent could become the first biological drug against chronic obstructive pulmonary disease (COPD). The pharmaceutical group points out that the latter is the third leading cause of death in the world and that no new treatment has been…
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service providers. They are kept for the duration of the processing and/or for the duration of the specific processing to which you have consented and/or for…
(AOF) – The European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) for the treatment of eosinophilic esophagitis in adults and adolescents from the age of 12, weighing at least 40 kg, who are inadequately controlled by conventional medicines or are intolerant to them or for whom these…
By Jean-Noel Legalland Published on 12/16/2022 at 1:48 p.m. Photo credit © Sanofi Corporate (Boursier.com) — Sanofi Indicates that the CHMP recommends the approval of Dupixent (dupilumab) in the EU for the treatment of eosinophilic esophagitis. The Committee…
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Tuesday evening that the Food and Drug Administration (FDA), the American health authority, had approved Dupixent for the treatment of patients aged six months to five years with Moderate to severe atopic dermatitis not controlled by topical prescription medications or for which these medications are not recommended….
(AOF) – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) 300 mg once weekly for the treatment of eosinophilic esophagitis in patients ages 12 and older, weighing at least 40 kg. “With this approval, Dupixent becomes the first and only drug specifically indicated for the treatment of eosinophilic esophagitis in the United…
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Friday evening that the Food and Drug Administration (FDA), the American health authority, had authorized the use of its drug Dupixent for the treatment of patients aged 12 and more with eosinophilic esophagitis. “With this approval, Dupixent becomes the first and only drug specifically indicated for the…
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi confirmed on Thursday that it is aiming for further growth in its net earnings per share (EPS) from activities in 2022, after performing significantly above analysts’ expectations in the first quarter. “We are off to a particularly strong start to 2022, driven by the continued remarkable performance of Dupixent”…
